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http://dx.doi.org/10.10injury (TBI) is associated with an increased incidence of neurological disease and psychiatric comorbid-
ities, including chronic traumatic encephalopathy, Alzheimer’s disease, Parkinson’s disease, and amyo-
trophic lateral sclerosis. These epidemiologic studies, however, do not offer a clear definition of that risk,
and leave unanswered the bounding criteria for greater lifetime risk of neurodegeneration. Key factors
that likelymediate the degree of risk of neurodegeneration include genetic factors, significant premorbid
and comorbid medical history (e.g. depression, multiple head injuries and repetitive subconcussive
impact to the brain, occupational risk, age at injury, and severity of brain injury). However, given the
often-described concerns in self-report accuracy as it relates to history of multiple TBIs, low frequency
of patient presentation to a physician in the case of mild brain injuries, and challengeswith creating clear
distinctions between injury severities, disentangling the true risk for neurodegeneration based solely on
population-based studieswill likely remain elusive.Given this reality,multiplemodalities andapproaches
must be combined to characterize who are at risk so that appropriate interventions to alter progression of
neurodegeneration can be evaluated. This article presents data from a study that highlights uses of neuro-
imaging and areas of needed research in the link between TBI and neurodegenerative disease.
 2014 Published by Elsevier Inc. on behalf of The Alzheimer’s Association.Keywords: Traumatic brain injury; Repetitive TBI; Dementia; Neuroimaging1. Introduction
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nt matter  2014 Published by Elsevier Inc. on behalf of Th
16/j.jalz.2014.04.002identify those at increased risk of neurodegeneration in acute
and chronic traumatic brain injury (TBI). It is one of the few
methods that allows in vivo, noninvasive assessments of
neurobiology. The challenge with defining the role is that
we do not have a single imaging modality that meets all
the following criteria: (1) accessible and safe for use in acute
injury in those with altered consciousness. (2) equally sensi-
tive to all injury severities, (3) equally sensitive to the acute
through chronic time course, and (4) appropriate for the
identification of the earliest of pathological changes in the
transition to neurodegenerative disease. Practically, thise Alzheimer’s Association.
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uum (or continuous variable), we triage and segregate our
imaging tools in a large part by injury severity (to be treated
as categorical). This is a challenge in terms of identifying
factors that predict who will be at greater risk for neurode-
generation, and the precipitating cause for increased concern
because these factors likely can be found in all stages of
injury (e.g. less than full recovery in mild without acute im-
aging, delayed recovery in repeated TBI, and magnetic reso-
nance imaging in the chronic stage only, with less than full
recovery). Also complicating this challenge is that there is
an understandable disconnect between the clinical need
and motivation for imaging and the lack of sensitivity of
that imaging across our continuum.
Neuroimaging does provide some degree of diagnostic
value in TBI (e.g. identification by computed tomographic
scan of blood product or swelling after moderate to severe
injury), characterization of acute reaction to injury (e.g. posi-
tron emission tomographic ligands for inflammation), quanti-
ficationof injury severity (e.g. quantificationofdegreeofwhite
matter damage assessed via diffusion tensor imaging), assess-
ment of degreeof alterationof functional networks (e.g. resting
state functional magnetic resonance imaging), and chronic
progressive alterations (e.g. changes in cortical thickness,
atrophy, alterations in biochemistry of high-risk brain regions).
These tools, taken together with changes in screening and
management of brain injury, and ongoing studies in high-risk
populations can inform risk for neurodegeneration.
To provide an initial foundation for future work in identi-
fying neuroimaging-based markers of risk for neurodegener-
ation, we set out to characterize the effects of single and
multiple concussion in a chronic, largely recovered (having
returned to work or school after injury and not seeking clin-
ical care for symptoms related to the TBI), civilian popula-
tion. Neuropsychological testing was also conducted in
part to characterize the population, and in part to allow cor-
relation with tissue volume.Table 1
TBI severity definitions [1,3]
Severity LOC AOC PTA GCS, pt
Mild 0–30 min 0.01 min–24 h ,24 h 13
Grade I 0 min ,15 min
Grade II 0 min .15 min
Grade III 0.01–30 min
Moderate 30 min–24 h .24 hours and
,7 days
9–12
Severe .24 hours .7 days ,8
Abbreviations: AOC, alteration of consciousness, GCS, Glasgow Coma
Scale; LOC, loss of consciousness; PTA, posttraumatic amnesia.2. Methods
This study was approved by the human subjects commit-
tee of the University of Illinois–Chicago and is consistent
with all local and federal requirements for human subjects
research. All participants provided written informed consent
before participation. A total of 80 participants were recruited
at the University of Illinois Medical Center via advertise-
ments in the community seeking individuals who had ever
sustained a closed head injury, concussion, brain injury, or
TBI.
We used a minimum definition for TBI consistent with
the memorandum issued by the Assistant Secretary for De-
fense [1]. ATBI is defined as “a traumatically induced struc-
tural injury and/or physical disruption of brain function as a
result of an external force that is indicated by new onset or
worsening of at least one of the following clinical signs,
immediately following the event: any period of loss of ordecreased level of consciousness; any loss of memory for
events immediately before or after the injury; neurologic
deficits; intracranial lesion” [1].
In reference to TBI injury severity, we adopted the stan-
dards from the American Congress on Rehabilitation Medi-
cine (ACRM) [2], the American Academy of Neurology
Practice Guidelines on concussion grading [3], and the
report on definition of TBI and TBI severity from the Assis-
tant Secretary for Defense [1]. It is important to note that
although the ACRM includes the Glascow Coma Scale
(GCS) as one method for determining severity in the acute
stage, the Department of Defense definition does not [1].
In addition, it has been reported that more than 60% of sol-
diers (in the early years of theWar on Terror) with confirmed
TBI were never assessed for GCS score. This report also in-
cludes a category for defining severity based on duration of
altered consciousness and loss of consciousness [1]. Severity
is defined by duration and presence of loss of consciousness,
alteration in mental status and duration of alteration of con-
sciousness, posttraumatic amnesia for events leading up to or
following the injury, and focal neurological defects. For the
present study we use both the Department of Defense defini-
tion of TBI [1] and the American Academy of Neurology
Practice Guidelines for definitions within the mild TBI spec-
trum [3] (Table 1).
According to the ACRM guidelines, 47 participants
were classified as having a history of mild closed head
TBI at least 6 months from injury. Of the 43 participants
with mild TBI, 14 reported a history of multiple mild
TBIs (range, 2–3). Comparisons between mild TBI with
a single injury and multiple injuries did not yield any sig-
nificant differences on any neuropsychological, demo-
graphic, or imaging measures. None of the participants
were recruited from active clinical practice, but instead
responded to advertisements in local papers, flyers, or ad-
vertisements on Craig’s List. Thirty-seven healthy control
subjects were also recruited from the community to match
the participants with TBI in terms of age, years of educa-
tion, years of employment, and estimated premorbid intel-
ligence (Table 2). Participants (control and TBI) were
excluded if they had a history of psychiatric disorder
before the TBI, substance abuse/dependency, current or
past litigation, failure on a formal measure of effort, or
any other neurological or medical condition that could
Table 2
Participant, injury, and group characteristics
Sample characteristics Mild TBI Composite 1 TBI .1 TBI Control subjects
Sample size n 5 43 n 5 29 n 5 14 n 5 37
No. of women (%) 20 (47) 14 (49) 6 (43) 21 (57)
Age at MRI, y 34 (20–58) 35 (20–58) 33 (21–51) 33 (19–60)
Age at TBI, y 29 (16–57) 30 (16–57) 28 (16–48) NA
MMSE score out of 30 pt, pt 29 (26–30) 29 (26–30) 29 (28–30) 29 (25–30)
Estimated IQ 112 (80–123) 112 (80–123) 112 (87–121) 111 (84–123)
No. with LOC (%) 24 (56) 14 (48) 10 (71) NA
Average time since TBI, y 5.3 (0.5–28) 5.7 (0.5–21) 4.4 (0.5–28) NA
Average length of LOC, h 0.07 (0–0.5) 0.08 (0–0.5) 0.03 (0–0.5) NA
Average length of PTA, h 0.47 (0–1) 0.47 (0–1) 0.48 (0–1) NA
No. with posttraumatic seizure (%) 1 (2) 1 (3) 0 (0) NA
No. with posttraumatic headache (%) 25 (58) 15 (52) 10 (72) NA
No. with other significant injuries (%) 15 (35) 12 (41) 3 (22) NA
No. employed/student at TBI (no. returned
to work/school after TBI)
41 (39) 28 (26) 13 (13) NA
Abbreviations: LOC, loss of consciousness; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; NA, not applicable; PTA, posttrau-
matic amnesia; TBI, traumatic brain injury.
NOTE. Unless indicated otherwise, data are shown as mean (range). Loss of consciousness data for mild TBI with more than one injury is for greatest severity
injury (longest loss of consciousness or longest posttraumatic amnesia). Please note that MMSE data were available only for 26 control subjects and 31 par-
ticipants with mild TBI. Also, there were no significant differences among groups (P , .01) for age at study, highest levels of education or employment, pre-
morbid IQ, or MMSE score.
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chronic pain). Participants were not receiving any psychi-
atric medication or medications used for cognitive
enhancement at the time of the study. Detailed demo-
graphic information is presented in Table 2. Statistical
comparisons among groups with regard to age at the
time of assessment, educational attainment, Mini-Mental
State Examination score, estimated IQ, age at the time
of the injury, and other TBI variables identified no signif-
icant differences among any of the groups.
The mechanism of injury varied and included motor
vehicle accidents (n 5 10), pedestrian motor vehicle acci-
dents (n5 3), assault (n5 3), sports related (n5 8), and falls
or blows to the head (n 5 14).2.1. Neuropsychological testing
Participants completed a neuropsychological test battery
that was assembled to assess executive function, attention,
and memory. Because of the prevalence of executive func-
tion impairments in TBI, the battery was weighed more
heavily on executive measures. Tests included the Stroop
[4–6], Trail Making Test [7], Continuous Performance Test
[8], Controlled Oral Word Association Test [9,10], Ruff
Figural Fluency [11], forward and backward Digit Span
[12], Spatial Span [12], California Verbal Learning Test
[13], Brief Visual Memory Test [14], Mini-Mental State Ex-
amination [15–17], Wechsler Test of Adult Reading [18],
Test of Memory Malingering [20,21], and Dot Counting
Task [19]. Additional details on these tests, battery, and justi-
fication for domain score calculation can be found in work
by others [22–24].2.2. Voxel-based morphometry
Magnetic resonance images were analyzed with SPM5
(Wellcome Department of Neurology, London, UK).
SPM5 was run using MATLAB 7.0.1 (Mathworks, Natick,
MA). Data for each subject was aligned in the axial, coronal,
and sagittal planes. Images were then normalized spatially to
the Montreal Neurological Institute T1 template and
smoothed using an 8-mm full-width at half maximum
Gaussian kernel. The final preprocessing step was segmenta-
tion into gray matter, white matter, and cerebrospinal fluid
(CSF) at a 1 ! 1 ! 1-mm voxel size. Primary analyses
were conducted among subject groups (control subjects, par-
ticipants with mild TBI, participants with moderate–severe
TBI). Threshold masking was set to 0.01. Correlations
were carried out between tissue concentration and key injury
variables (loss of consciousness, length of posttraumatic
amnesia, time from injury), cognitive status (executive func-
tion, memory, attention), and mood. A false discovery rate
(FDR) of p(FDR) less than 0.001 was applied to all contrasts
among groups.
2.3. Statistical analysis
Neuropsychological test scores were converted to Z-
scores (mean, 0; standard deviation, 1) based on the control
mean and standard deviation, then averaged to derive com-
posite domain scores. Two different types of analyses were
conducted on the neuropsychological data. First, the primary
analysis was a two-way repeated-measures analysis of vari-
ance (ANOVA), with cognitive domain (executive, attention,
memory) as the within-subjects factor and subject group as
the between-subjects factor. Second, directed one-way
D.M. Little et al. / Alzheimer’s & Dementia 10 (2014) S188-S195 S191ANOVAs comparing groups within each domain score were
also conducted.3. Results
3.1. Neuropsychological testing
With regard to neuropsychological domain scores, there
was no interaction between cognitive domain and subject
group: F(2,160) 5 1.436, P 5 .241, h2 5 0.20. And,
although there was a trend for poorer performance from
the participants with mild TBI relative to the control sub-
jects, this main effect was not significant: F(1,80) 5 3.637,
P 5 .060, h2 5 0.048. However, follow-up comparisons
within each cognitive domain and among groups did demon-
strate a significant reduction in overall executive function for
the participants with mild TBI relative to control subjects:
F(1,80) 5 7.000, P 5 .008. The groups did not differ on
either attention or memory domains. Results from one-way
ANOVAs on all three domain scores and each individual
test are presented in Table 3. These data were then converted
to Z-scores relative to the control group mean. Fig. 1 shows
how both groups of participants with mild TBIs performed
relative to control subjects.3.2. Whole-brain volumetric analysis
Before voxel-wise comparisons using voxel-based
morphometry (VBM), whole-brain volumes were extractedTable 3




CPT hit reaction time, msec 392.87
Tower of London, total no. of moves 105.61
Stroop Color–Word, age corrected, seconds 48.53
PASAT total correct 138.53
Trails B, sec 52.64
CPT, number of omissions 10.25
COWAT total score 43.83
RUFF Unique Designs, t score 45.77
Digit Span Backward, items recalled 8.58
Spatial Span Backward, items recalled 8.44
Attention domain 0.00
Digit Span Forward, items recalled 11.17
Spatial Span Forward, items recalled 9.75
Trail Making Test Part A, sec 23.36
CPT, number of omissions 2.56
Memory domain 0.00
CVLT trials 1–5, total recalled 57.44
CVLT Long-Free Recall, total recalled 12.50
BVMT trials 1–3, total recalled 27.19
BVMT Delay Recall, total recalled 9.92
Abbreviations: ANOVA, analysis of variance; BVMT, Brief Visual Memory Te
formance Test; CVLT, California Verbal Learning Test; PASAT, Paced Auditory Se
the mean; TBI, traumatic brain injury.
*P , .05.from each subject group to include total intracranial volume
(TIV), total intracranial gray matter volume, total intracra-
nial white matter volume, and total CSF volumes. First, there
was no effect of participant group on TIV (F 5 0.069,
P5 .933, h25 0.001). Second, there was an effect of partic-
ipant group on TIV gray matter (F 5 34.797, P , .001,
h2 5 0.406) and white matter (F 5 5.625, P 5 .005,
h2 5 0.099), and on TIV CSF (F 5 4.957, P 5 .009,
h2 5 0.089).
The same patterns of results were found when gray matter
volume, white matter volume, and CSF were controlled for
TIV, representing the relative proportion of gray matter,
white matter, and CSF. As would be expected, given the
nonsignificant effects of subject group on TIV, the pattern
of statistical results is identical to that mentioned earlier.
Specifically, there was an effect of participant group on
gray matter (F 5 13.370, P , .001, h2 5 0.208) and white
matter (F 5 7.651, P 5 .001, h2 5 0.130), and on CSF
(F 5 3.958, P 5 .022, h2 5 0.072).3.3. Groupwise VBM results
Comparisons were conducted among control and TBI
participants for both cerebral gray and white matter. Areas
of significant decrease in intensity in participants with
mild TBI relative to control subjects were found in both
the gray and white matter. Overall, for those with a single
TBI, there were relatively few changes. With regard to whitewith mild TBI organized by domain
Mild TBI
ANOVASEM Mean SEM
0.10 20.37 0.10 0.008*
12.35 366.17 9.85 0.294
2.45 99.05 2.61 0.072
1.77 44.84 1.62 0.127
7.36 124.32 6.51 0.152
3.69 65.00 5.57 0.071
1.08 13.71 1.07 0.025*
1.96 41.05 1.81 0.301
2.07 44.07 1.44 0.500
0.37 7.32 0.43 0.029*
0.31 8.13 0.32 0.484
0.10 20.14 0.10 0.315
0.42 11.03 0.39 0.807
0.32 8.92 0.36 0.088
1.94 24.71 1.28 0.559
1.01 2.05 0.63 0.673
0.15 20.28 0.13 0.151
1.62 53.29 1.77 0.088
0.54 11.53 0.50 0.189
0.97 25.53 0.78 0.181
0.30 9.74 0.28 0.661
st; COWAT, Controlled Oral Word Association Test; CPT, Continuous Per-
rial Addition Test; RUFF, Ruff Figural Fluency Test; SEM, standard error of
Fig. 1. Normalized (Z-scored) neuropsychological performance of groups
with mild traumatic brain injury (TBI; 1 mild TBI, n 5 29; .1 mild TBI,
n5 14) relative to control subjects (mean for control subjects, 0.0). Shaded
box represents 1 standard deviation around the control mean. A, attention; E,
executive function; M, memory.
Fig. 2. Areas of significant alteration in tissue density as assessed with
voxel-based morphometry. Regions shown indicate lower density for mild
traumatic brain injury in the cerebral white matter relative to control sub-
jects.
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the right internal capsule and right ventrolateral prefrontal
white matter (Fig. 2).
There were many different areas of tissue density change
observed in the gray matter in participants with mild TBI
relative to control subjects, with indicators of significant at-
rophy in the somatosensory, parietal, temporal, parahippo-
campal, and cerebellar regions (Fig. 3).
We then examined differences between those with a sin-
gle TBI vs. those with a history of two to three mild TBIs.
Those with a history of multiple mild TBIs showed
decreased tissue density in the temporal lobes, parahippo-
campal gyri, ventrolateral prefrontal regions external
capsule, and cerebellum (Fig. 4).4. Correlations between VBM and cognition (within
group)
Voxel-wise bivariate correlations were conducted for the
combined white and gray matter VBM maps relative to ex-
ecutive, attention, and memory domain scores for the partic-
ipants with mild TBI. Interesting, executive function was
associated with decreased tissue concentrations in the poste-
rior cingulate and increased concentrations in the internal
capsule for participants with mild TBI. With regard to atten-
tion, the cingulate, parietal and occipital white matter, and
temporal gray matter were associated with improved perfor-
mance. Within the mild TBI group, memory function wasassociated with reductions in tissue concentration in the par-
ahippocampal gyri, anterior temporal lobe, and internal
capsule.
In summary, there does appear to be an effect on tissue
concentration from even one mild TBI. However, it is un-
likely that these data suggest that all participants with a his-
tory of mild TBI are at risk for poorer outcomes. In fact,
when we normalized the volumetric data relative to control
subjects and examined the z-distribution of volumes within
participants with mild TBI, only 14 fell below two standard
deviations of the control mean. This highlights the need to
move from examination of group data into examinations of
neuroimaging modalities relative to prognostic value. It is
unclear, however, what that end point prognostic indicator
should be. Our data do, however, suggest that atrophy, how-
ever sensitive to volumetric changes, is likely to be one
marker that is worth including in the ultimate risk definition
model, if one is created to inform individual patient risk.5. Discussion
Although the mechanisms that underlie increased risk for
onset of neurodegenerative disease in patients with a history
of TBI are not currently known, neuroimaging can and will
be important in developing methods to identify those at risk,
to monitor those individuals in a noninvasive way, to be use-
ful in the prediction of disease progression, and, potentially,
to have a significant role in evaluating early intervention
effectiveness. Furthermore, neuroimaging can also have a
role in helping define the gross acute and chronic differences
in those who may be at a differential risk. However, it is crit-
ical that “significant” findings between and within groups be
interpreted within the context of symptom severity and
impairment, and not overreach into prediction of risk based
on nonspecific imaging markers.
Volumetric assessments of acute, chronic, and progres-
sive changes in cerebral tissue will inform one part of the
Fig. 3. Areas of significant alteration in tissue density as assessed with voxel-based morphometry. Regions shown indicate lower density for mild traumatic
brain injury in the cerebral gray matter relative to control subjects.
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outcomes. As our data demonstrate, for the first time, there
are chronic alterations in a recovered mild TBI population,
and these alterations do reflect cognitive function even in
those who have returned to work or school successfully after
their injuries. These data raise two important mechanistic
questions in how we begin to address neurodegenerativeFig. 4. Areas of significant alteration in tissue density as assessed with voxel-base
than one TBI relative to those participants with mild TBI with a history of one TBrisk in this population. One mechanistic question, which
cannot be answered using neuroimaging alone, is: What
acute or chronic factors lead to alterations in tissue volume,
and what role does injury severity play in increased or
decreased risk? The second mechanistic question is: Which,
if any, of these alterations are clinically relevant and, if so, at
what threshold? The population recruited in the current studyd morphometry for mild traumatic brain injury (TBI) with a history of more
I.
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a focus on mild TBI, recruitment of those without loss of
consciousness, and lack of recruitment of those seeking or
in clinical care for symptoms after TBI. Yet, there are find-
ings of chronic alterations in tissue density and, taken
together with previous reports, it is likely these changes
are progressive and not present until a chronic stage [25].
However, when viewed relative to the epidemiologic litera-
ture and grossly normal neuropsychological assessments, it
seems unlikely that these markers of volumetric tissue loss
are clinically relevant indicators of risk at this specific stage
of injury chronicity. We propose that, until the mechanisms
that lead to tissue loss are identified, such neuroimaging
markers—in a nonsymptomatic patient group—be consid-
ered a marker not of neurodegenerative risk itself, but instead
a marker of potential biological vulnerability.
This suggestion leads to the most significant challenge in
the application of neuroimaging for assessment of neurode-
generative risk: the lack of causative biochemical and bio-
logical alterations that drive group differences in derived
neuroimaging markers. In other words, neuroimaging pro-
vides a nonspecific indication of biological alteration and
lacks specificity for the mechanism of impairment and risk
for neurodegeneration. Furthermore, the relatively weak cor-
relations between calculated and derived neuroimaging
measures and those that assess clinical outcome complicate
the interpretation of the meaningfulness of these measures
further. In vivo animal imaging combined with ex vivo as-
says can help disentangle what these measures mean more
specifically, and can move neuroimaging further away
from being simply descriptive. Neuroimaging can provide
the foundation for baseline assessment of brain structure
and function, identify factors that correlate with acute and
chronic injury, and characterize the progression to dementia
in those who follow that risk path. Better animal models and
imaging of these models are needed.
In addition, there must be a significant move toward the
integration of coherent data analytical plans that allow
movement beyond voxel-wise comparisons between
groups, to a structure that integrates clinical and neuroi-
maging markers. One example of such an approach is the
application of machine learning models that allow assess-
ments of networks, rather than voxels, relative to meaning-
ful clinical data.
The biggest concern, however, is identifying the signifi-
cant differences between control subjects, patients with
mild TBI, and those with multiple mild injuries. From the
data presented, one can find differences among groups
even in those with a single mild injury. It is likely that a small
proportion of these patients will have poorer outcomes, but
the gross majority will recover and be at no additional
risk. Adaptation of more traditional clinical evaluation
methods and application of these methods to neuroimaging
data and results reporting will be beneficial.
Although there are primary studies that link TBI to long-
term neurodegeneration, there is still a need for the detectionsmall injuries at their earliest signs of development. The
increased emphasis on the comorbidity of TBI with a wide
spectrum of neurological disorders beyond Alzheimer’s dis-
ease (AD), such as chronic traumatic encephalopathy, and
Parkinson’s disease should place additional development
of TBI neuroimaging as a high priority for research.
AD neuroimaging shares several parallels with TBI neu-
roimaging research. Both have robust strategies for strati-
fying patient populations, but clinical presentation still
remains divorced from diagnostic testing. It is hoped that
research in both spaces will converge so that the interrela-
tionship between TBI and neurodegenerative disease can
be better understood. Imaging represents a unique nexus
by which this could be accomplished, which could lead to
new diagnostic criteria for TBI/AD and a better understating
of the longitudinal effects of TBI. This could, subsequently,
power studies on the efficacy of cognitive behavioral thera-
pies or even pharmacological interventions.
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